After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data
Researchers, clinicians and executives react to Compass Pathways’ second positive Phase 3 psilocybin readout in treatment-resistant depression.
psychedelicalpha.com/news/after-t...
Researchers, clinicians and executives react to Compass Pathways’ second positive Phase 3 psilocybin readout in treatment-resistant depression.